Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Chris Denton, MD
Professor of Experimental Rheumatology and Consultant Rheumatologist and Centre Head, Royal Free Hospital
Principal Investigator - Robert Spiera, MD
Professor of Clinical Medicine, Weill Cornell Medical College
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
74 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Royal Adelaide Hospital
Adelaide, Australia
- Liverpool Hospital
Liverpool, Australia
- St Vincent'S Hospital
Melbourne, Australia
- Royal Prince Alfred Hospital
Sydney, Australia
- Sir Mortimer B. Davis Jewish General Hospital
Montreal, Canada
- the Arthritis Centre
Winnipeg, Canada
- Universitätsklinikum Heidelberg
Heidelberg, Baden-Wurttemberg, Germany
- Charité- Universitätsmedizin Berlin, Klinik Für Rheumatologie Und Klinische Immunologie, Abteilung -Neue Therapien & Studien-
Berlin, Germany
- University Hospital Cologne, Department of Dermatology and Venereology
Cologne, Germany
- Universitätsklinik Köln,klinik Und Poliklinik Für Dermatologie Und Venerologie
Cologne, Germany
- Department of Internal Medicine 3, University of Erlangen-Nuremberg
Erlangen, Germany
- University Medical Center Freiburg
Freiburg im Breisgau, Germany
- Kerckhoff-Klinik Gmbh, Zentrum Rheumatologie U. Klin. Immunologie, Studienambulanz
Nauheim, Germany
- University Hospital Ulm
Ulm, Germany
- Bnai Zion Medical Center
Haifa, Israel
- Rambam Health Corporation
Haifa, Israel
- Meir Medical Center - Internal Medicine E
Kfar Saba, Israel
- Sheba Medical Center
Ramat Gan, Israel
- Kyushu University Hospital
Fukuoka, Japan
- Kanazawa University Hospital
Kanazawa, Japan
- Gunma University Hospital
Maebashi, Japan
- Hokkaido University Hospital
Sapporo, Japan
- National University Corporation Tohoku University Tohoku University Hospital
Sendai, Japan
- Osaka University Hospital
Suita, Japan
- Nippon Medical School Hospital
Tokyo, Japan
- Yokohama City University Hospital
Yokohama, Japan
- Leiden University Medical Center
Leiden, South Holland, Netherlands
- Erasmus Medical Center
Rotterdam, Netherlands
- Haga Hospital
The Hague, Netherlands
- Samodzielny Publiczny Szpital Kliniczny Nr 1; Katedra I Klinika Dermatologii, Wenerologii I Dermatologii Dziecięcej Uniwersytetu Medycznego W Lublinie
Lublin, Poland
- Medyczne Centrum Hetmanska
Poznan, Poland
- Reum-Medica S.C
Wroclaw, Poland
- Asan Medical Center
Seoul, South Korea
- Hanyang University Medical Center
Seoul, South Korea
- Seoul National University Hospital
Seoul, South Korea
- the Catholic University of Korea, Seoul St. Mary'S Hospital
Seoul, South Korea
- Hospital Universitari de la Santa Creu I Sant Pau
Barcelona, Spain
- Hospital Universitario Doctor Peset
Valencia, Spain
- Cantonal Hospital St. Gallen
Sankt Gallen, Switzerland
- University Hospital Zurich
Zurich, Switzerland
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 18 Dec 2017
- Primary completion
- 27 May 2020
- Completion
- 21 Dec 2020
- Last update posted
- 29 Mar 2021
- Registered enrollment
- 365
- Registry id
- NCT03398837
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.